scholarly journals Respiratory health and quality of life in young exclusive, habitual smokers - a comparison of waterpipe smokers, cigarette smokers and non-smokers

2019 ◽  
Vol Volume 14 ◽  
pp. 1813-1824 ◽  
Author(s):  
F.I. Hawari ◽  
N.A. Obeidat ◽  
M. Abu Alhalawa ◽  
Z. Al-Busaidi ◽  
B. Amara ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Respiratory Health ◽  
Cigarette Smokers

Respiratory health impacts quality of life for adults with OI

2019 ◽  
Author(s):  
Elizabeth Yonko ◽  
Erin Carter ◽  
Robert Sandhaus ◽  
Cathleen Raggio
Keyword(s):  
Quality Of Life ◽  
Respiratory Health ◽  
Health Impacts

Adults face increased asthma risk after infant RSV bronchiolitis and reduced respiratory health-related quality of life after RSV pneumonia

2014 ◽  
Vol 103 (8) ◽  
pp. 850-855 ◽  
Author(s):  
Katri Backman ◽  
Eija Piippo-Savolainen ◽  
Hertta Ollikainen ◽  
Heikki Koskela ◽  
Matti Korppi
Keyword(s):  
Quality Of Life ◽  
Respiratory Health ◽  
Health Related Quality ◽  
Asthma Risk ◽  
Related Quality ◽  
Health Related

scholarly journals Ventilated cookstoves associated with improvements in respiratory health-related quality of life in rural Bolivia

2013 ◽  
Vol 36 (3) ◽  
pp. 460-466 ◽  
Author(s):  
Donee Alexander ◽  
Jacqueline Callihan Linnes ◽  
Susan Bolton ◽  
Timothy Larson
Keyword(s):  
Quality Of Life ◽  
Respiratory Health ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

scholarly journals Stigma from medication use: an under recognised burden of care

Breathe ◽  
2021 ◽  
Vol 17 (1) ◽  
pp. 210002
Author(s):  
Sonal Kansra ◽  
Rachel Calvert ◽  
Steve Jones
Keyword(s):  
Quality Of Life ◽  
Disease Control ◽  
Respiratory Health ◽  
List Type ◽  
Social Environments ◽  
Burden Of Care ◽  
Children And Young People ◽  
Educational Aims ◽  
Spheres Of Influence

Children with respiratory diseases take treatments for the self-management of symptoms and to maintain disease control. Often, these treatments need to be taken in social environments like school. Respiratory treatments can foster a feeling of difference and stigmatisation, which negatively impact on the quality of life and adherence to treatment. Such perceptions can lead to a less than optimal disease control, a vicious cycle leading to further social exclusion and stigma. This aspect of “burden of treatment” is poorly recognised by clinicians. Recognition of how treatments and clinical practice can contribute to stigma, can help address this burden of care.Educational aimsTo understand the meaning of the term “stigma” within the context of respiratory health conditions and how medication or treatments can contribute to stigma in children and young people.To understand the potential impact of stigma on adherence, disease control and quality of life.To consider strategies to manage the stigma associated with health treatments across spheres of influence.

Impact of respiratory muscle training on respiratory muscle strength, respiratory function and quality of life in individuals with tetraplegia: a randomised clinical trial

Thorax ◽  
2020 ◽  
Vol 75 (3) ◽  
pp. 279-288 ◽  
Author(s):  
Claire L Boswell-Ruys ◽  
Chaminda R H Lewis ◽  
Nirupama S Wijeysuriya ◽  
Rachel A McBain ◽  
Bonsan Bonne Lee ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Muscle Strength ◽  
Lung Function ◽  
Respiratory Muscle ◽  
Respiratory Health ◽  
Inspiratory Muscle ◽  
Respiratory Muscle Training ◽  
Muscle Training ◽  
Inspiratory Muscle Strength

BackgroundRespiratory complications remain a leading cause of morbidity and mortality in people with acute and chronic tetraplegia. Respiratory muscle weakness following spinal cord injury-induced tetraplegia impairs lung function and the ability to cough. In particular, inspiratory muscle strength has been identified as the best predictor of the likelihood of developing pneumonia in individuals with tetraplegia. We hypothesised that 6 weeks of progressive respiratory muscle training (RMT) increases respiratory muscle strength with improvements in lung function, quality of life and respiratory health.MethodsSixty-two adults with tetraplegia participated in a double-blind randomised controlled trial. Active or sham RMT was performed twice daily for 6 weeks. Inspiratory muscle strength, measured as maximal inspiratory pressure (PImax) was the primary outcome. Secondary outcomes included lung function, quality of life and respiratory health. Between-group comparisons were obtained with linear models adjusting for baseline values of the outcomes.ResultsAfter 6 weeks, there was a greater improvement in PImax in the active group than in the sham group (mean difference 11.5 cmH2O (95% CI 5.6 to 17.4), p<0.001) and respiratory symptoms were reduced (St George Respiratory Questionnaire mean difference 10.3 points (0.01–20.65), p=0.046). Significant improvements were observed in quality of life (EuroQol-Five Dimensional Visual Analogue Scale 14.9 points (1.9–27.9), p=0.023) and perceived breathlessness (Borg score 0.64 (0.11–1.17), p=0.021). There were no significant improvements in other measures of respiratory function (p=0.126–0.979).ConclusionsProgressive RMT increases inspiratory muscle strength in people with tetraplegia, by a magnitude which is likely to be clinically significant. Measurement of baseline PImax and provision of RMT to at-risk individuals may reduce respiratory complications after tetraplegia.Trial registration numberAustralian New Zealand Clinical Trials Registry (ACTRN 12612000929808).

scholarly journals Respiratory Health and Related Quality of Life in Patients with Congenital Agammaglobulinemia in the Northern Region of the UK

2016 ◽  
Vol 36 (5) ◽  
pp. 472-479 ◽  
Author(s):  
Branwen A. Bryan ◽  
Alex Battersby ◽  
Benjamin Martin James Shillitoe ◽  
Dawn Barge ◽  
Helen Bourne ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Respiratory Health ◽  
Northern Region ◽  
Related Quality ◽  
The Uk

scholarly journals Immunomodulatory Effect of Charak Immunity Tablets (CIT) On Healthy Participants: A Single Blind, Randomized, Placebo-Controlled, Exploratory Study

2021 ◽  
Author(s):  
Akanksha Mourya ◽  
Amit Yadav ◽  
Suresh Khadke ◽  
Sarika Mane ◽  
Asavari Joshi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Perceived Stress ◽  
Exploratory Study ◽  
Mononuclear Cells ◽  
Immune Status ◽  
Respiratory Health ◽  
Objective Assessment ◽  
Healthy Individuals ◽  
Single Blind

Immunity has become an important aspect of concern, as the spread of corona virus, is on the rise. The strategies to boost and modulate the immunity have therefore become need of the hour. The present study was carried out to evaluate the effect of Charak immunity Tablets (CIT) on innate and adaptive immune response in healthy individuals. It was a single-blind, randomized, placebo-controlled, exploratory study. After obtaining Ethics Committee permission, 36 healthy individuals of either sex aged 18-35 years with prior consent were recruited in the study. They were randomly divided into 2 groups to receive either CIT or Placebo in 2:1 ratio. Both the interventions were given in a dose of 1 tab (500 mg) twice daily. The assessment variables were vitals [temperature, pulse, and blood pressure], respiratory health [respiratory rate, oxygen saturation and peak expiratory flow rate], questionnaire based assessment of immune status, perceived stress and quality of life along with objective assessment of immunity [CD4+, CD8+ counts, Interferon gamma (IFN &gamma;), Tumor necrosis factor alpha (TNF-&alpha;) and Interleukin 10 (IL-10)] as well as oxidative stress; [Malondialdehyde (MDA) and Glutathione peroxidase], which were assessed at fixed time points. Of 36 recruited participants, only 18 participants completed the study. CIT treated individuals showed a statistically significant improvement in respiratory health, quality of life, perceived stress and subjective immune status. There was a decrease in the levels of serum IFN &gamma; on day 60 compared to baseline. TNF-&alpha; and IL-10, both estimated from supernatant of Peripheral Blood Mononuclear Cells (PBMCs) stimulated with lipopolysaccharide (LPS), showed a decrease and a significant increase respectively on day 60 compared to baseline in CIT group. Further, CIT significantly decreased MDA levels.The present study indicates that CIT is an effective and safe drug to boost immunity. However, our findings need to be confirmed in larger sample size using more specific immune parameters.

Sign in / Sign up

Export Citation Format

Share Document